AMLX Healthcare

Amylyx Pharmaceuticals, Inc.

$29.20+4.14%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 3.7B USD
Enterprise value: 3.0B USD
Full-time employees: 136

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #967 of 1,157 healthcare companies (bottom 17%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 68% from December 2022 to July 2026.
Amylyx Pharmaceuticals had 68% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Amylyx Pharmaceuticals had 68% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Amylyx Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Amylyx Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Revenue is falling. Revenue fell 100% in the 12 months to June 2026 vs the 12 months before.
Amylyx Pharmaceuticals's revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

StockQuotient Score

31/ 100

Oct 5 32 → Nov 4 31 (-1)

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-4.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-5.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield7.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

8/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth-100.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

13/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-57.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -11.02Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-67.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.19Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-63.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio12.12×

SEC filings · latest balance sheetReported value33% base weight · Z-score 6.88Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.98Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Amylyx Pharmaceuticals

Is Amylyx Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 6, 2026) showed no major changes. Its overall score is unchanged at 31/100 since Oct 28, 2026.
How is Amylyx Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.7% vs peers 1.5% (weaker than 100% of peers).
Is Amylyx Pharmaceuticals growing?: More slowly than most of its peers. Growth scores 8/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).
How profitable is Amylyx Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 13/100 against 1,393 healthcare peers. Return on assets -57.5% vs a peer median of 1.7% (weaker than 95% of peers).Return on assets -57.5% vs peers 1.7% (weaker than 95% of peers).
How risky is Amylyx Pharmaceuticals?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 12.12× vs a peer median of 2.59× (stronger than 90% of peers).Current ratio 12.12× vs peers 2.59× (stronger than 90% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Aug 6, 2026 · compared with the quarter ended Sep 30, 2025

No major changes

Worth watching: Amylyx Pharmaceuticals is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	−665,000 USD	0 USD	turned positive
Net income (12 months)	−149.3M USD	−152.1M USD	+1.9%
Free cash flow (12 months)	−154.5M USD	−126.7M USD	−18.0%
Cash	225.2M USD	49.3M USD	−78.1%
Shares outstanding	109.8M	111.4M	+1.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	86.5%	93.3%	93.2%	—	—
Operating margin	-29013.3%	-905.7%	10.2%	-360.2%	—	—
Net margin	-30853.0%	-892.4%	12.9%	-345.4%	—	—
Return on assets (ROA)	-83.3%	-50.7%	9.5%	-155.8%	-43.5%	▲ 112 pts
Return on equity (ROE)	—	-58.2%	11.4%	-183.1%	-47.4%	▲ 136 pts
Free cash flow margin	-26369.1%	-820.5%	2.8%	-192.1%	—	—
Current ratio	6.03×	8.20×	5.66×	6.67×	14.27×	▲ 114%
Quick ratio	—	7.99×	5.20×	6.67×	—	—

AMLX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #967 of 1,157 healthcare companies (bottom 17%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 68% from December 2022 to July 2026.

Amylyx Pharmaceuticals had 68% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Amylyx Pharmaceuticals had 68% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Amylyx Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Amylyx Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Revenue is falling. Revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

Amylyx Pharmaceuticals's revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

Questions investors ask about Amylyx Pharmaceuticals

Is Amylyx Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 6, 2026) showed no major changes. Its overall score is unchanged at 31/100 since Oct 28, 2026.

How is Amylyx Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.7% vs peers 1.5% (weaker than 100% of peers).

Is Amylyx Pharmaceuticals growing?

More slowly than most of its peers. Growth scores 8/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).

How profitable is Amylyx Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 13/100 against 1,393 healthcare peers. Return on assets -57.5% vs a peer median of 1.7% (weaker than 95% of peers).Return on assets -57.5% vs peers 1.7% (weaker than 95% of peers).

How risky is Amylyx Pharmaceuticals?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 12.12× vs a peer median of 2.59× (stronger than 90% of peers).Current ratio 12.12× vs peers 2.59× (stronger than 90% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

−665,000 USD

0 USD

turned positive

Net income (12 months)

−149.3M USD

−152.1M USD

+1.9%

Free cash flow (12 months)

−154.5M USD

−126.7M USD

−18.0%

Cash

225.2M USD

49.3M USD

−78.1%

Shares outstanding

109.8M

111.4M

+1.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

86.5%

93.3%

93.2%

—

Operating margin

-29013.3%

-905.7%

10.2%

-360.2%

—

Net margin

-30853.0%

-892.4%

12.9%

-345.4%

—

Return on assets (ROA)

-83.3%

-50.7%

9.5%

-155.8%

-43.5%

▲ 112 pts

Return on equity (ROE)

—

-58.2%

11.4%

-183.1%

-47.4%

▲ 136 pts

Free cash flow margin

-26369.1%

-820.5%

2.8%

-192.1%

—

Current ratio

6.03×

8.20×

5.66×

6.67×

14.27×

▲ 114%

Quick ratio

—

7.99×

5.20×

6.67×

—